Mycoplasma Testing Market By Product, By Technology, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The Mycoplasma Testing Market was valued at $0.7 billion in 2022 and is estimated to reach $2,243.10 million by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.

Mycoplasma testing is used to detect the presence of mycoplasma contamination in cell culture samples. Mycoplasma is a type of bacteria that lacks a cell wall and is difficult to detect and remove from cell cultures. Mycoplasma contamination can cause various problems in cell cultures, such as altered growth characteristics, changes in gene expression, and compromised experimental results. Therefore, it is essential to regularly test cell cultures for mycoplasma contamination to ensure the accuracy and reliability of experimental results. Mycoplasma testing is important in the process of testing vaccines, virus cultures, and other biopharmaceuticals.

The mycoplasma testing market growth is driven by an increase in demand for biologics & biosimilars, a surge in incidences of cell culture contamination, and a rise in the adoption of novel technologies for drug development. Biologics and biosimilars are complex drugs produced using living cells, and they can be contaminated by mycoplasma during the manufacturing process. Thus, regulatory bodies such as Food and Drug Administration (FDA) and European Medicines Agency (EMA) require biologics and biosimilars to be tested for mycoplasma contamination before they are approved for use. This has created a surge in demand for mycoplasma testing services. For instance, according to the IQVIA report on the Impact of Biosimilar Competition in Europe in 2021, about 9 biosimilars were approved in 2020 and 7 approved in 2021. Thus, the rise in the approval and demand for biologics & biosimilars has resulted in increased demand for mycoplasma testing.

Furthermore, the rise in incidences of cell culture contamination in the biopharmaceutical industry and the globalization of clinical trials are the key factors that boost market growth. As clinical trials are conducted across multiple countries and regions, there is a need for mycoplasma testing services that can ensure the safety of trial participants and the accuracy of trial data. This has led to an increasing demand for mycoplasma testing services and products that meet standardized testing requirements.

However, the high cost of mycoplasma testing products limits their adoption in biopharmaceutical companies, which, in turn, restrains the market growth. For instance, the cost of SouthernBiotech's Mycoplasma Detection Kit used for the detection of mycoplasma contamination in cell cultures is around $200-230. In addition, the price of culture-based mycoplasma testing service is about $250-300 per sample. Thus, the high cost of mycoplasma testing products and services negatively impacts market growth.

On the other hand, the increase in demand for mycoplasma testing in developed and developing countries such as U.S., Germany, and China is expected to create immense opportunities for the mycoplasma testing market during the forecast period.

The mycoplasma testing market is segmented on the basis of product, technology, application, end-user, and region. On the basis of product, the market is categorized into instruments, kits & reagents, and services. On the basis of technology, the market is divided into PCR, ELISA, microbial culture techniques, and enzymatic methods. On the basis of application, the market is classified into cell line testing, virus testing, end-of-production cell testing, and others. On the basis of end users, the market is segregated into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global mycoplasma testing market are: ATCC, Bionique Testing Laboratories LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., InvivoGen, Lonza, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mycoplasma testing market analysis from 2022 to 2032 to identify the prevailing mycoplasma testing market opportunities.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the mycoplasma testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes analysis of the regional as well as global mycoplasma testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

Instruments
Kits and Reagents
Services

By Technology

PCR
ELISA
Microbial Culture Techniques
Enzymatic Methods

By Application

Cell Line Testing
Virus Testing
End of Production Cells Testing
Others

By End User

Academic Research Institutes
Cell Banks
Contract Research Organizations
Pharmaceutical and Biotechnology Companies
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

ATCC
Bionique Testing Laboratories LLC
Bio-Rad Laboratories, Inc.
Charles River Laboratories
Eurofins Scientific
F. Hoffmann-La Roche Ltd.
InvivoGen
Lonza
Norgen Biotek Corp.
Thermo Fisher Scientific Inc.

Product Code: A11266

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Surge in demand for mycoplasma testing
  - 3.4.1.2. Increase in incidences of cell culture contamination

3.4.2. Restraints
- 3.4.2.1. High cost of mycoplasma testing kits and instruments

3.4.3. Opportunities
- 3.4.3.1. Developing economies offer lucrative opportunities
- 3.4.3.2. Rise in technological advancements

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Instruments
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Kits and Reagents
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Services
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY

5.1. Overview
- 5.1.1. Market size and forecast
5.2. PCR
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. ELISA
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Microbial Culture Techniques
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Enzymatic Methods
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Cell Line Testing
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Virus Testing
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. End of Production Cells Testing
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Academic Research Institutes
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Cell Banks
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Contract Research Organizations
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
7.5. Pharmaceutical and Biotechnology Companies
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by region
- 7.5.3. Market share analysis by country
7.6. Others
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by region
- 7.6.3. Market share analysis by country

CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key trends and opportunities
- 8.2.2. Market size and forecast, by Product
- 8.2.3. Market size and forecast, by Technology
- 8.2.4. Market size and forecast, by Application
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Key market trends, growth factors and opportunities
  - 8.2.6.1.2. Market size and forecast, by Product
  - 8.2.6.1.3. Market size and forecast, by Technology
  - 8.2.6.1.4. Market size and forecast, by Application
  - 8.2.6.1.5. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Key market trends, growth factors and opportunities
  - 8.2.6.2.2. Market size and forecast, by Product
  - 8.2.6.2.3. Market size and forecast, by Technology
  - 8.2.6.2.4. Market size and forecast, by Application
  - 8.2.6.2.5. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Key market trends, growth factors and opportunities
  - 8.2.6.3.2. Market size and forecast, by Product
  - 8.2.6.3.3. Market size and forecast, by Technology
  - 8.2.6.3.4. Market size and forecast, by Application
  - 8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key trends and opportunities
- 8.3.2. Market size and forecast, by Product
- 8.3.3. Market size and forecast, by Technology
- 8.3.4. Market size and forecast, by Application
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Key market trends, growth factors and opportunities
  - 8.3.6.1.2. Market size and forecast, by Product
  - 8.3.6.1.3. Market size and forecast, by Technology
  - 8.3.6.1.4. Market size and forecast, by Application
  - 8.3.6.1.5. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Key market trends, growth factors and opportunities
  - 8.3.6.2.2. Market size and forecast, by Product
  - 8.3.6.2.3. Market size and forecast, by Technology
  - 8.3.6.2.4. Market size and forecast, by Application
  - 8.3.6.2.5. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Key market trends, growth factors and opportunities
  - 8.3.6.3.2. Market size and forecast, by Product
  - 8.3.6.3.3. Market size and forecast, by Technology
  - 8.3.6.3.4. Market size and forecast, by Application
  - 8.3.6.3.5. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Key market trends, growth factors and opportunities
  - 8.3.6.4.2. Market size and forecast, by Product
  - 8.3.6.4.3. Market size and forecast, by Technology
  - 8.3.6.4.4. Market size and forecast, by Application
  - 8.3.6.4.5. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Key market trends, growth factors and opportunities
  - 8.3.6.5.2. Market size and forecast, by Product
  - 8.3.6.5.3. Market size and forecast, by Technology
  - 8.3.6.5.4. Market size and forecast, by Application
  - 8.3.6.5.5. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Key market trends, growth factors and opportunities
  - 8.3.6.6.2. Market size and forecast, by Product
  - 8.3.6.6.3. Market size and forecast, by Technology
  - 8.3.6.6.4. Market size and forecast, by Application
  - 8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key trends and opportunities
- 8.4.2. Market size and forecast, by Product
- 8.4.3. Market size and forecast, by Technology
- 8.4.4. Market size and forecast, by Application
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Key market trends, growth factors and opportunities
  - 8.4.6.1.2. Market size and forecast, by Product
  - 8.4.6.1.3. Market size and forecast, by Technology
  - 8.4.6.1.4. Market size and forecast, by Application
  - 8.4.6.1.5. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Key market trends, growth factors and opportunities
  - 8.4.6.2.2. Market size and forecast, by Product
  - 8.4.6.2.3. Market size and forecast, by Technology
  - 8.4.6.2.4. Market size and forecast, by Application
  - 8.4.6.2.5. Market size and forecast, by End User
  - 8.4.6.3. Australia
  - 8.4.6.3.1. Key market trends, growth factors and opportunities
  - 8.4.6.3.2. Market size and forecast, by Product
  - 8.4.6.3.3. Market size and forecast, by Technology
  - 8.4.6.3.4. Market size and forecast, by Application
  - 8.4.6.3.5. Market size and forecast, by End User
  - 8.4.6.4. India
  - 8.4.6.4.1. Key market trends, growth factors and opportunities
  - 8.4.6.4.2. Market size and forecast, by Product
  - 8.4.6.4.3. Market size and forecast, by Technology
  - 8.4.6.4.4. Market size and forecast, by Application
  - 8.4.6.4.5. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Key market trends, growth factors and opportunities
  - 8.4.6.5.2. Market size and forecast, by Product
  - 8.4.6.5.3. Market size and forecast, by Technology
  - 8.4.6.5.4. Market size and forecast, by Application
  - 8.4.6.5.5. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Key market trends, growth factors and opportunities
  - 8.4.6.6.2. Market size and forecast, by Product
  - 8.4.6.6.3. Market size and forecast, by Technology
  - 8.4.6.6.4. Market size and forecast, by Application
  - 8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key trends and opportunities
- 8.5.2. Market size and forecast, by Product
- 8.5.3. Market size and forecast, by Technology
- 8.5.4. Market size and forecast, by Application
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Key market trends, growth factors and opportunities
  - 8.5.6.1.2. Market size and forecast, by Product
  - 8.5.6.1.3. Market size and forecast, by Technology
  - 8.5.6.1.4. Market size and forecast, by Application
  - 8.5.6.1.5. Market size and forecast, by End User
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Key market trends, growth factors and opportunities
  - 8.5.6.2.2. Market size and forecast, by Product
  - 8.5.6.2.3. Market size and forecast, by Technology
  - 8.5.6.2.4. Market size and forecast, by Application
  - 8.5.6.2.5. Market size and forecast, by End User
  - 8.5.6.3. South Africa
  - 8.5.6.3.1. Key market trends, growth factors and opportunities
  - 8.5.6.3.2. Market size and forecast, by Product
  - 8.5.6.3.3. Market size and forecast, by Technology
  - 8.5.6.3.4. Market size and forecast, by Application
  - 8.5.6.3.5. Market size and forecast, by End User
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Key market trends, growth factors and opportunities
  - 8.5.6.4.2. Market size and forecast, by Product
  - 8.5.6.4.3. Market size and forecast, by Technology
  - 8.5.6.4.4. Market size and forecast, by Application
  - 8.5.6.4.5. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Thermo Fisher Scientific Inc.
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
10.2. Charles River Laboratories
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
10.3. Lonza
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
10.4. F. Hoffmann-La Roche Ltd.
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
10.5. Bio-Rad Laboratories, Inc.
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
10.6. Eurofins Scientific
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
10.7. ATCC
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
10.8. Bionique Testing Laboratories LLC
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
10.9. InvivoGen
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
10.10. Norgen Biotek Corp.
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio